cutaneous T-cell lymphoma (CTCL)

From Aaushi
Jump to navigation Jump to search

Etiology

Clinical manifestations

Laboratory

Radiology

Complications

Management

* purine analog, histone deacetylase inhibitor, monoclonal Ab

More general terms

More specific terms

Additional terms

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Aljishi M, Barrow C Cutaneous T-Cell Lymphoma N Engl J Med 2015; 372:2437. June 18, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26083208 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMicm1406401
  2. 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  3. 3.0 3.1 3.2 Wu J, Wood GS. Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study. JAMA Dermatol. Published online August 29, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30167641 https://jamanetwork.com/journals/jamadermatology/fullarticle/2697566
  4. 4.0 4.1 Garlewicz J Cutaneous T-Cell Lymphoma and Psoriasis Associated With Memory Impairment. The Dermatologist. Aug 8, 2022 https://www.hmpgloballearningnetwork.com/site/thederm/news/cutaneous-t-cell-lymphoma-and-psoriasis-associated-memory-impairment
    Damiani G, Tacastacas JD, Wuerz T et al. Cognition/psychological burden and resilience in cutaneous T-cell lymphoma and psoriasis patients: real-life data and implications for the treatment. Biomed Res Int. Published online July 21, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35937394 PMCID: PMC9348939 Free PMC article

Patient information

cutaneous T-cell lymphoma patient information